Lu177-DOTA-octreotate therapy on neuroendocrine tumour management: A case report and literature review

Authors

  • Georgios Bartseas Nuclear Medicine Dpt Evangelismos General Hospital Athens, Greece
  • Nektarios Alevizopoulos Department of Oncology, Evagelismos General Hospital of Athens, Greece.
  • Lina Skoura Nuclear Medicine Dpt Evangelismos General Hospital Athens, Greece
  • Eirini Xousianakou Nuclear Medicine Dpt Evangelismos General Hospital Athens, Greece
  • Michael Vaslamatzis Department of Oncology, Evagelismos General Hospital of Athens, Greece.
  • Ioannis Datseris Nuclear Medicine Dpt Evangelismos General Hospital Athens, Greece

DOI:

https://doi.org/10.2015/hc.v11i2.732

Keywords:

Peptide receptor radionuclide therapy (PRRT), Lu177-DOTA-octreotate, Neuroendocrine tumors (NET).

Abstract

Favourable outcomes of peptide receptor radiotherapy of neuroendocrine tumors have been reported during the last years. This case report refers to a patient with a non-functional neuroendocrine carcinoma of pancreas with liver metastases and abdominal lymph nodes involvement. He underwent fractionated treatment with 4 cycles of Lu177-DOTA-octreoate (7.400MBq) after the failure of treatment with chemotherapy regiments. We conclude that fractionated therapy with Lu177-DOTA-octreotate should be considered a treatment option in the management of patients for symptomatic improvement in inoperable or metastasized neuroendocrine tumors, and for patients with large tumors and high somatostatin receptor expression.

Downloads

Additional Files

Published

2016-04-05

Issue

Section

CASE REPORTS